Innate Pharma Toekomstige groei

Future criteriumcontroles 2/6

Innate Pharma zal naar verwachting groeien in winst en omzet met respectievelijk 38.1% en 25.8% per jaar. De winst per aandeel zal naar verwachting groeien met 93.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -132.3% zijn.

Belangrijke informatie

38.1%

Groei van de winst

93.9%

Groei van de winst per aandeel

Biotechs winstgroei	35.7%
Inkomstengroei	25.8%
Toekomstig rendement op eigen vermogen	-132.3%
Dekking van analisten	Good
Laatst bijgewerkt	13 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:IDDA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	102	-14	70	174	5
12/31/2025	85	10	35	99	6
12/31/2024	53	-32	12	12	6
6/30/2024	34	-34	-20	-18	N/A
3/31/2024	48	-21	-28	-25	N/A
12/31/2023	62	-8	-35	-33	N/A
9/30/2023	57	-35	-34	-32	N/A
6/30/2023	52	-63	-33	-32	N/A
3/31/2023	55	-60	-27	-25	N/A
12/31/2022	58	-58	-20	-19	N/A
9/30/2022	57	-40	-24	-23	N/A
6/30/2022	57	-22	-28	-26	N/A
3/31/2022	41	-34	-44	-42	N/A
12/31/2021	25	-45	-60	-58	N/A
6/30/2021	46	-8	-27	-25	N/A
3/31/2021	58	-4	-45	-38	N/A
12/31/2020	70	-1	-63	-52	N/A
9/30/2020	67	-54	-78	-67	N/A
6/30/2020	63	-44	-93	-83	N/A
3/31/2020	75	-33	-62	-24	N/A
12/31/2019	85	8	-30	35	N/A
9/30/2019	108	5	-17	48	N/A
6/30/2019	130	31	-4	61	N/A
3/31/2019	112	17	-19	14	N/A
12/31/2018	94	3	-34	-33	N/A
9/30/2018	70	-19	-49	-46	N/A
6/30/2018	46	-40	-64	-59	N/A
3/31/2018	45	-44	N/A	-53	N/A
12/31/2017	44	-48	N/A	-48	N/A
9/30/2017	55	-28	N/A	-43	N/A
6/30/2017	66	-8	N/A	-38	N/A
3/31/2017	66	3	N/A	-37	N/A
12/31/2016	66	13	N/A	-37	N/A
9/30/2016	53	5	N/A	-33	N/A
6/30/2016	41	-2	N/A	-29	N/A
3/31/2016	33	-4	N/A	86	N/A
12/31/2015	25	-7	N/A	202	N/A
9/30/2015	17	-13	N/A	200	N/A
6/30/2015	8	-19	N/A	199	N/A
3/31/2015	8	-19	N/A	91	N/A
12/31/2014	8	-20	N/A	-18	N/A
9/30/2014	11	-15	N/A	-15	N/A
6/30/2014	14	-10	N/A	-12	N/A
3/31/2014	15	-6	N/A	-11	N/A
12/31/2013	17	-3	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IDDA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IDDA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IDDA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IDDA ( 25.8% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.5% per jaar).

Hoge groei-inkomsten: De omzet van IDDA ( 25.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat IDDA binnen 3 jaar verliesgevend zal zijn.

Innate Pharma Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven